The health benefits of resveratrol have been proven to inhibit the development of numerous diseases. A frequent limitation in its use is a low bioavailability stemming from a poor solubility and fast enterohepatic metabolism. Thus, the aim of the research was to investigate the possibility to formulate mucoadhesive cyclodextrin- and xanthan gum-based buccal tablets in order to increase the solubility of resveratrol and to eliminate bypass enterohepatic metabolism. Systems of resveratrol with α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD) and 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) prepared by the dry mixing method (ratio 1:1) were selected for the of tablets where xanthan gum was used as a mucoadhesive agent. They were identified on the basis of PXRD, FT-IR analysis. Tablets F1 (with α-CD), F2 (with β-CD) and F3 (with γ-CD) were characterized by the highest compactibility as well as by favorable mucoadhesive properties. Resveratrol release from these tablets was delayed and controlled by diffusion. The tablets prepared in the course of this study appear to constitute promising resveratrol delivery systems and are recommended to increase the effectiveness of the treatment in many diseases, particularly periodontitis.

Department of Chemical Engineering University of Chemistry and Technology Prague Technická 3 166 28 Prague Czech Republic

Department of Chemical Technology of Drugs Poznan University of Medical Sciences Grunwaldzka 6 60 780 Poznań Poland

Department of Conservative Dentistry and Endodontics Poznan University of Medical Sciences Bukowska 70 60 812 Poznań Poland

Department of Pharmaceutical Technology Faculty of Pharmacy Medical University of Białystok Mickiewicza 2c 15 222 Białystok Poland

Department of Pharmacognosy Poznan University of Medical Sciences Święcickiego 4 60 781 Poznań Poland

Zentiva k s U Kabelovny 130 102 37 Praha Czech Republic

Zobrazit více v PubMed

Pihlstrom B.L., Michalowicz B.S., Johnson N.W. Periodontal diseases. Lancet. 2005;366:1809–1820. doi: 10.1016/S0140-6736(05)67728-8. PubMed DOI

Popova C., Dosseva-Panova V., Panov V. Microbiology of Periodontal Diseases. A Review. Biotechnol. Biotechnol. Equip. 2013;27:3754–3759. doi: 10.5504/BBEQ.2013.0027. DOI

Eid Abdelmagyd H.A., Ram Shetty D.S., Musa Musleh Al-Ahmari D.M. Herbal medicine as adjunct in periodontal therapies—A review of clinical trials in past decade. J. Oral. Biol. Craniofac. Res. 2019;9:212–217. doi: 10.1016/j.jobcr.2019.05.001. PubMed DOI PMC

Kala R., Tollefsbol O.T., Li Y. Potential of Resveratrol in Inhibiting Cancer and Slowing Aging. J. Nutr. Food Sci. 2012;5:5. doi: 10.4172/2155-9600.S5-001. DOI

Khazaei S., Khazaei M., Kazemi S., Yaghini J. Resveratrol as a supplemental treatment for periodontitis. Dent. Res. J. 2012;9:655–657. doi: 10.4103/1735-3327.104891. PubMed DOI PMC

Li J., Wu T., Peng W., Zhu Y. Effects of resveratrol on cariogenic virulence properties of Streptococcus mutans. BMC Microbiol. 2020;20:1–11. doi: 10.1186/s12866-020-01761-3. PubMed DOI PMC

Andrade E.F., Orlando D.R., Araújo A.M.S., De Andrade J.N.B.M., Azzi D.V., De Lima R.R., Lobo-Júnior A.R., Pereira L.J. Can Resveratrol Treatment Control the Progression of Induced Periodontal Disease? A Systematic Review and Meta-Analysis of Preclinical Studies. Nutrients. 2019;11:953. doi: 10.3390/nu11050953. PubMed DOI PMC

Bonechi C., Lamponi S., Donati A., Tamasi G., Consumi M., Leone G., Rossi C., Magnani A. Effect of resveratrol on platelet aggregation by fibrinogen protection. Biophys. Chem. 2017;222:41–48. doi: 10.1016/j.bpc.2016.12.004. PubMed DOI

Lu R., Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 1999;179:297–304. doi: 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P. PubMed DOI

Mgbonyebi O.P., Russo J., Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 1998;12:865–869. doi: 10.3892/ijo.12.4.865. PubMed DOI

Gomes B.A.Q., Silva J.P.B., Romeiro C.F.R., Dos Santos S.M., Rodrigues C.A., Gonçalves P.R., Sakai J.T., Mendes P.F.S., Varela E.L.P., Monteiro M.C. Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1. Oxidative Med. Cell. Longev. 2018;2018:1–15. doi: 10.1155/2018/8152373. PubMed DOI PMC

Oyenihi O.R., Oyenihi A.B., Adeyanju A.A., Oguntibeju O.O. Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility. J. Diabetes Res. 2016;2016:1–14. doi: 10.1155/2016/9737483. PubMed DOI PMC

Stivala L.A., Savio M., Carafoli F., Perucca P., Bianchi L., Maga G., Forti L., Pagnoni U.M., Albini A., Prosperi E., et al. Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol. J. Biol. Chem. 2001;276:22586–22594. doi: 10.1074/jbc.M101846200. PubMed DOI

Spogli R., Bastianini M., Ragonese F., Iannitti R.G., Monarca L., Bastioli F., Nakashidze I., Brecchia G., Menchetti L., Codini M., et al. Solid Dispersion of Resveratrol Supported on Magnesium DiHydroxide (Resv@MDH) Microparticles Improves Oral Bioavailability. Nutrients. 2018;10:1925. doi: 10.3390/nu10121925. PubMed DOI PMC

Smoliga J.M., Blanchard O. Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? Molecules. 2014;19:17154–17172. doi: 10.3390/molecules191117154. PubMed DOI PMC

Walle T., Hsieh F., DeLegge M., Oatis J., Jr., Walle K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004;32:1377–1382. doi: 10.1124/dmd.104.000885. PubMed DOI

Walle T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011;1215:9–15. doi: 10.1111/j.1749-6632.2010.05842.x. PubMed DOI

Chimento A., De Amicis F., Sirianni R., Sinicropi M.S., Puoci F., Casaburi I., Saturnino C., Pezzi V. Progress to Improve Oral Bioavailability and Beneficial Effects of Resveratrol. Int. J. Mol. Sci. 2019;20:1381. doi: 10.3390/ijms20061381. PubMed DOI PMC

Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005;49:472–481. doi: 10.1002/mnfr.200500010. PubMed DOI

Almeida L., Vaz-Da-Silva M., Falcão A., Soares E., Costa R., Loureiro A.I., Fernandes-Lopes C., Rocha J.-F., Nunes T., Wright L., et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res. 2009;53:S7–S15. doi: 10.1002/mnfr.200800177. PubMed DOI

Loftsson T., Brewster M.E. Cyclodextrins as Functional Excipients: Methods to Enhance Complexation Efficiency. J. Pharm. Sci. 2012;101:3019–3032. doi: 10.1002/jps.23077. PubMed DOI

Conceição J., Adeoye O., Cabral-Marques H.M., Lobo J.M.S. Cyclodextrins as excipients in tablet formulations. Drug Discov. Today. 2018;23:1274–1284. doi: 10.1016/j.drudis.2018.04.009. PubMed DOI

Amri A., Chaumeil J., Sfar S., Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J. Control. Release. 2012;158:182–193. doi: 10.1016/j.jconrel.2011.09.083. PubMed DOI

Conceição J., Adeoye O., Cabral-Marques H.M., Lobo J.M.S. Hydroxypropyl-β-Cyclodextrin and β-Cyclodextrin as Tablet Fillers for Direct Compression. AAPS PharmSciTech. 2018;19:2710–2718. doi: 10.1208/s12249-018-1115-z. PubMed DOI

De Vries K., Strydom M., Steenkamp V. Bioavailability of resveratrol: Possibilities for enhancement. J. Herb. Med. 2018;11:71–77. doi: 10.1016/j.hermed.2017.09.002. DOI

Zhang H., Zhang J., Streisand J.B. Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2002;41:661–680. doi: 10.2165/00003088-200241090-00003. PubMed DOI

Blanchard O.L., Friesenhahn G., Javors M.A., Smoliga J.M. Development of a Lozenge for Oral Transmucosal Delivery of Trans-Resveratrol in Humans: Proof of Concept. PLoS ONE. 2014;9:e90131. doi: 10.1371/journal.pone.0090131. PubMed DOI PMC

Vaz-Da-Silva M., Loureiro A., Falcao A., Nunes T., Rocha J.-F., Fernandes-Lopes C., Soares E., Wright L., Almeida L., Soares-Da-Silva P. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int. J. Clin. Pharmacol. Ther. 2008;46:564–570. doi: 10.5414/CPP46564. PubMed DOI

Lopez-Nicolas J.M., Garcia-Carmona F. Aggregation state and pKa values of (E)-resveratrol as determined by fluorescence spectroscopy and UV-visible absorption. J. Agric. Food Chem. 2008;56:7600–7605. doi: 10.1021/jf800843e. PubMed DOI

Ansari M., Sadarani B., Majumdar A. Optimization and evaluation of mucoadhesive buccal films loaded with resveratrol. J. Drug Deliv. Sci. Technol. 2018;44:278–288. doi: 10.1016/j.jddst.2017.12.007. DOI

Martins I.C.F., Raposo N.R.B., Mockdeci H.R., Polonini H.C., Ferreira A.D.O., Fabri G.M.C., Chaves M.D.G.A.M. Delivering Resveratrol on the Buccal Mucosa Using Mucoadhesive Tablets: A Potential Treatment Strategy for Inflammatory Oral Lesions. Curr. Drug Deliv. 2018;15:254–259. doi: 10.2174/1567201814666170726102558. PubMed DOI

Bojanowski K., Bojanowski R. Two methods of oral delivery of resveratrol: A case study. J. Aging Res. Clin. Pract. 2015;4:185–189.

Paczkowska M., McDonagh A.F., Bialek K., Tajber L., Cielecka-Piontek J. Mechanochemical activation with cyclodextrins followed by compaction as an effective approach to improving dissolution of rutin. Int. J. Pharm. 2020;581:119294. doi: 10.1016/j.ijpharm.2020.119294. PubMed DOI

Moore J.W., Flanner H.H. Mathematical Comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech. 1996;20:64–74.

Chen K. The PAMPA Work Flow and Comparison of UV-Plate Reader Method vs. LC/MS Method. [(accessed on 4 March 2021)]; Available online: https://vdocuments.net/the-pampa-work-flow-and-comparison-of-uv-plate-permeability-formula-has-taken.html.

Yee S. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth. Pharm. Res. 1997;14:763–766. doi: 10.1023/A:1012102522787. PubMed DOI

Kikowska M.A., Chmielewska M., Włodarczyk A., Studzińska-Sroka E., Żuchowski J., Stochmal A., Kotwicka M., Thiem B. Effect of Pentacyclic Triterpenoids-Rich Callus Extract of Chaenomeles japonica (Thunb.) Lindl. ex Spach on Viability, Morphology, and Proliferation of Normal Human Skin Fibroblasts. Molecules. 2018;23:3009. doi: 10.3390/molecules23113009. PubMed DOI PMC

Apak R., Güçlü K., Özyürek M., Çelik S.E. Mechanism of antioxidant capacity assays and the CUPRAC (cupric ion reducing antioxidant capacity) assay. Microchim. ACTA. 2007;160:413–419. doi: 10.1007/s00604-007-0777-0. DOI

European Pharmacopoeia. 10th ed. Council of Europe Portal; Strasbourg, France: 2020. Uniformity of dosage units; pp. 398–400. Chapter 2.9.40.

Tye C.K., Sun C., Amidon G.E. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J. Pharm. Sci. 2005;94:465–472. doi: 10.1002/jps.20262. PubMed DOI

Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001;13:123–133. doi: 10.1016/S0928-0987(01)00095-1. PubMed DOI

Hassan E.E., Gallo J.M. A Simple Rheological Method for the in Vitro Assessment of Mucin-Polymer Bioadhesive Bond Strength. Pharm. Res. 1990;7:491–495. doi: 10.1023/A:1015812615635. PubMed DOI

Marques M.R.C., Loebenberg R., Almukainzi M. Simulated Biological Fluids with Possible Application in Dissolution Testing. Dissolution Technol. 2011;18:15–28. doi: 10.14227/DT180311P15. DOI

Nakamura F., Ohta R., Machida Y., Nagai T. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int. J. Pharm. 1996;134:173–181. doi: 10.1016/0378-5173(95)04416-7. DOI

Huang X., Dai Y., Cai J., Zhong N., Xiao H., McClements D.J., Hu K. Resveratrol encapsulation in core-shell biopolymer nanoparticles: Impact on antioxidant and anticancer activities. Food Hydrocoll. 2017;64:157–165. doi: 10.1016/j.foodhyd.2016.10.029. DOI

Zhou R., Wang F., Guo Z., Zhao Y.L. Preparation and characterization of resveratrol/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent technology. J. Food Process. Eng. 2012;35:1–10. doi: 10.1111/j.1745-4530.2010.00617.x. DOI

Kumpugdee-Vollrath M., Ibold Y., Sriamornsak P. Solid state characterization of trans resveratrol complexes with different cyclodextrins. JAASP. 2012;1:125–136.

Silva A.F.R., Monteiro M., Resende D., Braga S.S., Coimbra M.A., Silva A.M.S., Cardoso S.M. Inclusion Complex of Resveratrol with γ-Cyclodextrin as a Functional Ingredient for Lemon Juices. Foods. 2020;10:16. doi: 10.3390/foods10010016. PubMed DOI PMC

Dhakar N.K., Matencio A., Caldera F., Argenziano M., Cavalli R., Dianzani C., Zanetti M., López-Nicolás J.M., Trotta F. Comparative Evaluation of Solubility, Cytotoxicity and Photostability Studies of Resveratrol and Oxyresveratrol Loaded Nanosponges. Pharmaceutics. 2019;11:545. doi: 10.3390/pharmaceutics11100545. PubMed DOI PMC

Bertacche V., Lorenzi N., Nava D., Pini E., Sinico C. Host–Guest Interaction Study of Resveratrol with Natural and Modified Cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 2006;55:279–287. doi: 10.1007/s10847-006-9047-8. DOI

Lu Z., Cheng B., Hu Y., Zhang Y., Zou G. Complexation of resveratrol with cyclodextrins: Solubility and antioxidant activity. Food Chem. 2009;113:17–20. doi: 10.1016/j.foodchem.2008.04.042. DOI

Ansari K.A., Vavia P.R., Trotta F., Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: In vitro charac-terisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech. 2011;12:279–286. doi: 10.1208/s12249-011-9584-3. PubMed DOI PMC

Cooper G.M. The Cell: A Molecular Approach. 2nd ed. Sinauer Associates; Sunderland, MA, USA: 2000. Transport of Small Molecules.

Aree T., Jongrungruangchok S. Structure–antioxidant activity relationship of β-cyclodextrin inclusion complexes with olive tyrosol, hydroxytyrosol and oleuropein: Deep insights from X-ray analysis, DFT calculation and DPPH assay. Carbohydr. Polym. 2018;199:661–669. doi: 10.1016/j.carbpol.2018.07.019. PubMed DOI

Folch-Cano C., Jullian C., Speisky H., Olea-Azar C. Antioxidant activity of inclusion complexes of tea catechins with β-cyclodextrins by ORAC assays. Food Res. Int. 2010;43:2039–2044. doi: 10.1016/j.foodres.2010.06.006. DOI

Wang H., Wang S., Zhu H., Wang S., Xing J. Inclusion Complexes of Lycopene and β-Cyclodextrin: Preparation, Characterization, Stability and Antioxidant Activity. Antioxidants. 2019;8:314. doi: 10.3390/antiox8080314. PubMed DOI PMC

López-Nicolás J.M., Rodríguez-Bonilla P., García-Carmona F. Cyclodextrins and Antioxidants. Crit. Rev. Food Sci. Nutr. 2013;54:251–276. doi: 10.1080/10408398.2011.582544. PubMed DOI

EMA Cyclodextrins used as excipients. [(accessed on 19 March 2021)];Eur. Med. Agency. 2017 23:1–16. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/questions-answers-cyclodextrins-used-excipients-medicinal-products-human-use_en.pdf.

Sun C., Grant D.J.W. Influence of Crystal Structure on the Tableting Properties of Sulfamerazine Polymorphs. Pharm. Res. 2001;18:274–280. doi: 10.1023/A:1011038526805. PubMed DOI

Salústio P.J., Pontes P., Conduto C., Sanches I., Carvalho C., Arrais J., Marques H.M.C. Advanced Technologies for Oral Controlled Release: Cyclodextrins for Oral Controlled Release. AAPS PharmSciTech. 2011;12:1276–1292. doi: 10.1208/s12249-011-9690-2. PubMed DOI PMC

Ali A., Iqbal M., Akhtar N., Khan H.M.S., Ullah A., Uddin M., Khan M.T. Assessment of xanthan gum based sustained release matrix tablets containing highly water-soluble propranolol HCl. ACTA Pol. Pharm. Drug Res. 2013;70:283–289. PubMed

Gavini E., Rassu G., Haukvik T., Lanni C., Racchi M., Giunchedi P. Mucoadhesive microspheres for nasal administration of cyclodextrins. J. Drug Target. 2009;17:168–179. doi: 10.1080/10611860802556842. PubMed DOI

Wei B., Romero-Zerón L., Rodrigue D. Improved viscoelasticity of xanthan gum through self-association with surfactant: β-cyclodextrin inclusion complexes for applications in enhanced oil recovery. Polym. Eng. Sci. 2014 doi: 10.1002/pen.23912. DOI

Enhancing Bioavailability of Nutraceutically Used Resveratrol and Other Stilbenoids